JP6691044B2 - 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 - Google Patents

置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 Download PDF

Info

Publication number
JP6691044B2
JP6691044B2 JP2016528225A JP2016528225A JP6691044B2 JP 6691044 B2 JP6691044 B2 JP 6691044B2 JP 2016528225 A JP2016528225 A JP 2016528225A JP 2016528225 A JP2016528225 A JP 2016528225A JP 6691044 B2 JP6691044 B2 JP 6691044B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pro
compound
disease
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016528225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537338A5 (enExample
JP2016537338A (ja
Inventor
ニアリー，マイケル
ニーマン，ジェームズ
タニス，スティーブン
ロートン，ダニエル
スミス，ギャリー
Original Assignee
プロメンテイス・フアーマシユーテイカルズ・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロメンテイス・フアーマシユーテイカルズ・インコーポレイテツド filed Critical プロメンテイス・フアーマシユーテイカルズ・インコーポレイテツド
Publication of JP2016537338A publication Critical patent/JP2016537338A/ja
Publication of JP2016537338A5 publication Critical patent/JP2016537338A5/ja
Priority to JP2020069560A priority Critical patent/JP6952825B2/ja
Application granted granted Critical
Publication of JP6691044B2 publication Critical patent/JP6691044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/26—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C329/00—Thiocarbonic acids; Halides, esters or anhydrides thereof
    • C07C329/02—Monothiocarbonic acids; Derivatives thereof
    • C07C329/04—Esters of monothiocarbonic acids
    • C07C329/06—Esters of monothiocarbonic acids having sulfur atoms of thiocarbonic groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016528225A 2013-11-08 2014-11-07 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物 Active JP6691044B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020069560A JP6952825B2 (ja) 2013-11-08 2020-04-08 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361902052P 2013-11-08 2013-11-08
US61/902,052 2013-11-08
US201361902669P 2013-11-11 2013-11-11
US61/902,669 2013-11-11
PCT/US2014/064581 WO2015070034A1 (en) 2013-11-08 2014-11-07 Substituted n-acetyl-l-cysteine derivatives and related compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017213633A Division JP6559756B2 (ja) 2013-11-08 2017-11-06 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物
JP2020069560A Division JP6952825B2 (ja) 2013-11-08 2020-04-08 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物

Publications (3)

Publication Number Publication Date
JP2016537338A JP2016537338A (ja) 2016-12-01
JP2016537338A5 JP2016537338A5 (enExample) 2017-12-14
JP6691044B2 true JP6691044B2 (ja) 2020-04-28

Family

ID=51952031

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016528225A Active JP6691044B2 (ja) 2013-11-08 2014-11-07 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物
JP2017213633A Active JP6559756B2 (ja) 2013-11-08 2017-11-06 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物
JP2020069560A Active JP6952825B2 (ja) 2013-11-08 2020-04-08 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物
JP2021156357A Active JP7170811B2 (ja) 2013-11-08 2021-09-27 置換ｎ－アセチル－ｌ－システイン誘導体及び関連化合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017213633A Active JP6559756B2 (ja) 2013-11-08 2017-11-06 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物
JP2020069560A Active JP6952825B2 (ja) 2013-11-08 2020-04-08 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物
JP2021156357A Active JP7170811B2 (ja) 2013-11-08 2021-09-27 置換ｎ－アセチル－ｌ－システイン誘導体及び関連化合物

Country Status (14)

Country Link
US (7) US9012674B1 (enExample)
EP (2) EP3066089B1 (enExample)
JP (4) JP6691044B2 (enExample)
AU (3) AU2014346591B2 (enExample)
CA (1) CA2929655C (enExample)
DK (1) DK3066089T3 (enExample)
ES (1) ES2765236T3 (enExample)
HU (1) HUE048345T2 (enExample)
LT (1) LT3066089T (enExample)
PL (1) PL3066089T3 (enExample)
PT (1) PT3066089T (enExample)
SI (1) SI3066089T1 (enExample)
WO (1) WO2015070034A1 (enExample)
ZA (1) ZA201705288B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815905B2 (en) * 2010-03-10 2014-08-26 Promentis Pharmaceuticals, Inc. Propionic acids, propionic acid esters, and related compounds
PL3066089T3 (pl) * 2013-11-08 2020-04-30 Promentis Pharmaceuticals, Inc. Podstawione pochodne N-Acetylo-L-Cysteiny i związki pokrewne
CN107735094B (zh) 2015-06-05 2021-05-28 中国医药大学 胱氨酸-谷氨酸转运蛋白的抑制剂的新用途
US20180251431A1 (en) * 2016-12-09 2018-09-06 Vertex Pharmaceuticals Incorporated 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels
WO2018107040A1 (en) * 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated 1-(2-fluorophenyl)-n-[1-(2-fluoro-4-pyridyl)pyrazol-3-yl]cyclopropanecarboxamide, its solid forms and pharmaceutical uses thereof
US20190177295A1 (en) * 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Process for the preparation of a 1,3-disubstituted pyrazole compound
US20240425857A1 (en) 2021-10-29 2024-12-26 Vib Vzw Means and Methods for Chronic Wound Healing
CN116535998B (zh) * 2023-06-20 2024-05-17 安徽省阳明达新材料科技有限公司 一种热熔复合石材玻璃耐热eva胶片的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1493697A1 (de) * 1965-02-25 1969-11-20 Hoechst Ag Verfahren zur Spaltung von Thiolestern aromatischer Carbonsaeuren
IT1194117B (it) 1981-11-20 1988-09-14 Isnardi Pietro & C Spa Derivati salicilici di n-acetilcisteina
CN85107378A (zh) 1984-09-13 1987-03-18 陶氏化学公司 从原煤中回收有用煤的起泡剂组合物和泡沫浮选方法
US5637616A (en) 1993-06-18 1997-06-10 Arcturus Pharmaceutical Corporation Method for treating diseases mediated by proteases
AU1447095A (en) 1993-12-30 1995-07-17 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
WO1995034303A1 (en) 1994-06-13 1995-12-21 Arcturus Pharmaceutical Corporation Method for the treatment, prevention or minimization of hair loss
JP3608021B2 (ja) * 1996-09-05 2005-01-05 参天製薬株式会社 新規含硫黄アミノ酸誘導体
KR19990078146A (ko) 1998-03-24 1999-10-25 마키노 아라타 프로필렌계 수지 조성물 및 이를 사용한 연신필름
JP2002519341A (ja) * 1998-06-29 2002-07-02 パーカー ヒューズ インスティテュート 強力な抗がん剤としてのアルキルケトン類
AU6314200A (en) * 1999-07-26 2001-02-13 Toray Industries, Inc. Carboxylic acid derivatives and adhesion molecule inhibitors containing the sameas the active ingredient
AU2002333018B2 (en) 2001-09-27 2006-08-31 The Mental Health Research Institute Of Victoria Modulation of physiological processes and agents useful for same
CA2478066C (en) 2001-12-04 2009-09-08 Ben-Gurion University Of The Negev Research And Development Authority Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
CN1233629C (zh) 2002-11-22 2005-12-28 贵州省中国科学院天然产物化学重点实验室 具有神经营养作用的硫酯类化合物及其它的合成方法和应用
FR2856592B1 (fr) 2003-06-27 2008-04-25 Oreal Composition cosmetique a base de percuseur(s) de radical thiyl pour la deformation permanente des fibres keratiniques
JP2008538586A (ja) 2005-04-21 2008-10-30 グレン エー． ゴールドスタイン， 酸化ストレスに関連する疾患および病気の処置のためのｎ−アセチルシステインアミド（ｎａｃアミド）
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
WO2007042816A1 (en) 2005-10-12 2007-04-19 Biolipox Ab Benzoxazoles useful in the treatment of inflammation
CN101547703A (zh) * 2006-10-03 2009-09-30 加林制药公司 S-亚硝基硫醇化合物和相关衍生物
US7829709B1 (en) 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
WO2009100431A1 (en) * 2008-02-07 2009-08-13 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
WO2009137251A2 (en) 2008-04-16 2009-11-12 Marquette University Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings
US8524772B2 (en) 2008-05-09 2013-09-03 Tiara Pharmaceuticals, Inc. Controlled release of N-acetylcysteine (NAC) for reduction of systemic and/or vascular inflammation
AU2010224866C1 (en) 2009-03-16 2015-01-15 Genmedica Therapeutics Sl Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders
EP3138838A1 (en) 2010-01-29 2017-03-08 Dana-Farber Cancer Institute, Inc. Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders
US8815905B2 (en) 2010-03-10 2014-08-26 Promentis Pharmaceuticals, Inc. Propionic acids, propionic acid esters, and related compounds
EP2614821B1 (en) 2010-09-06 2016-11-09 SNU R & DB Foundation Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof
CA2816609A1 (en) * 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-t-butyl protected cysteine di-peptide analogs and related compounds
WO2012065110A2 (en) 2010-11-12 2012-05-18 Promentis Pharmaceuticals, Inc. S-protected cysteine analogs and related compounds
AU2012208283B2 (en) 2011-01-20 2017-01-05 Oneday - Biotech And Pharma Ltd. Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof
CA2842106A1 (en) 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
WO2014209412A1 (en) 2013-06-29 2014-12-31 Viva Pharmaceutical, Inc. N-acetyl l-cysteine chelates and methods for making and using the same
US20150038586A1 (en) 2013-07-10 2015-02-05 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of penetrating head injury
US20150133558A1 (en) 2013-10-15 2015-05-14 Glenn A. Goldstein Use of n-acetylcysteine amide for decreasing intracranial pressure
PL3066089T3 (pl) * 2013-11-08 2020-04-30 Promentis Pharmaceuticals, Inc. Podstawione pochodne N-Acetylo-L-Cysteiny i związki pokrewne
US20150209310A1 (en) 2014-01-24 2015-07-30 Brighton Biotech, Inc. Naca for the treatment of chronic or low impact brain trauma
US20150209309A1 (en) 2014-01-24 2015-07-30 Brighton Biotech, Inc Naca for the treatment of chronic or acute cognitive dysfunction

Also Published As

Publication number Publication date
AU2018282446A1 (en) 2019-01-17
US10961187B2 (en) 2021-03-30
US20210395194A1 (en) 2021-12-23
CA2929655A1 (en) 2015-05-14
US10112897B2 (en) 2018-10-30
JP6559756B2 (ja) 2019-08-14
US20240059649A1 (en) 2024-02-22
US20170183303A1 (en) 2017-06-29
JP6952825B2 (ja) 2021-10-27
EP3066089A1 (en) 2016-09-14
PT3066089T (pt) 2020-01-29
US20190315683A1 (en) 2019-10-17
US9630937B2 (en) 2017-04-25
AU2014346591A1 (en) 2016-05-26
AU2018282446B2 (en) 2020-07-23
DK3066089T3 (da) 2020-01-27
US9012674B1 (en) 2015-04-21
CA2929655C (en) 2023-06-13
ES2765236T3 (es) 2020-06-08
AU2014346591B2 (en) 2018-09-27
AU2020257084A1 (en) 2020-11-19
US10358414B2 (en) 2019-07-23
WO2015070034A1 (en) 2015-05-14
US20150133470A1 (en) 2015-05-14
HUE048345T2 (hu) 2020-07-28
EP3674297A1 (en) 2020-07-01
PL3066089T3 (pl) 2020-04-30
US20170210716A1 (en) 2017-07-27
JP2016537338A (ja) 2016-12-01
SI3066089T1 (sl) 2020-03-31
JP2022003063A (ja) 2022-01-11
JP2018080164A (ja) 2018-05-24
US20150133544A1 (en) 2015-05-14
JP2020121993A (ja) 2020-08-13
EP3066089B1 (en) 2019-11-06
ZA201705288B (en) 2019-02-27
JP7170811B2 (ja) 2022-11-14
LT3066089T (lt) 2020-02-25

Similar Documents

Publication Publication Date Title
JP6691044B2 (ja) 置換ｎ−アセチル−ｌ−システイン誘導体及び関連化合物
JP7061161B2 (ja) 核内輸送調節因子およびその使用
JP2021063104A (ja) 核内輸送調節因子およびその使用
US11124536B2 (en) Uridine nucleoside derivatives, compositions and methods of use
CN103119047A (zh) 三环类蛋白酶体活性增强化合物
FR2620121A1 (fr) ((pyrimidinyl-2)-aminoalkyl)-1 piperidines, leur preparation et leur application en therapeutique
KR20160130853A (ko) 신경변성 질환을 치료하기 조성물 및 방법
CN112218878A (zh) Ntcp抑制剂
US9193681B1 (en) Propionic acids, propionic acid esters, and related compounds
EA018024B1 (ru) Фенантреноновые соединения, композиции и способы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200409

R150 Certificate of patent or registration of utility model

Ref document number: 6691044

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250